{"id":"NCT02966795","sponsor":"AbbVie","briefTitle":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","officialTitle":"A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-25","primaryCompletion":"2018-06-06","completion":"2018-08-29","firstPosted":"2016-11-17","resultsPosted":"2019-07-10","lastUpdate":"2021-07-30"},"enrollment":84,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus (HCV)"],"interventions":[{"type":"DRUG","name":"Glecaprevir/Pibrentasvir","otherNames":["ABT-493/ABT-530","MAVYRETâ„¢"]}],"arms":[{"label":"Glecaprevir/Pibrentasvir for 8 Weeks","type":"EXPERIMENTAL"},{"label":"Glecaprevir/Pibrentasvir for 12 Weeks","type":"EXPERIMENTAL"}],"summary":"A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated cirrhosis respectively.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)","timeFrame":"12 weeks after last dose of study drug (week 20 or 24 depending on the treatment regimen)","effectByArm":[{"arm":"Genotype 5-infected","deltaMin":95.7,"sd":null},{"arm":"Genotype 6-infected","deltaMin":98.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":25,"countries":["United States","Australia","Belgium","Canada","France","New Zealand","Singapore","South Africa","Vietnam"]},"refs":{"pmids":["30393106","35174470"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":84},"commonTop":["FATIGUE","HEADACHE","DIZZINESS","NAUSEA","INSOMNIA"]}}